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Leiden, The NetherlandsAbstract Pharmacological blockade of the canna-
binoid type 1 receptor, a G protein-coupled receptor
expressed in the central nervous system and various
peripheral tissues, reverses diet-induced obesity
and dyslipidemia through the reduction of food
intake and altered nutrient partitioning. This strat-
egy is being explored for a number of therapeutic
applications; however, its potency for the treatment
of atherosclerotic cardiovascular disease via im-
provements in lipid metabolism remains unclear.
Therefore, here, we aimed to investigate whether
inhibition of the endocannabinoid system can
attenuate atherosclerosis development through
improvement of dyslipidemia. Lean, dyslipidemic
female APOE*3-Leiden.CETP transgenic mice were
fed a Western-type diet supplemented with or
without the cannabinoid type 1 receptor inverse
agonist rimonabant (20 mg⋅kg body weight¡1 day¡1)
for up to 20 weeks. Plasma lipids and bile acids were
determined, and atherosclerotic lesions were scored
in the aortic valve region. Rimonabant lowered
plasma levels of triglyceride (TG) (¡56%) and non-
HDL-C (¡19%) and increased HDL-C (þ57%). These
effects were explained by decreased VLDL-TG
production (¡52%) and accelerated VLDL-TG turn-
over accompanied by pronounced browning of
white adipose tissue. In addition, rimonabant
attenuated reverse cholesterol transport (¡30%),
increased plasma bile acid levels (þ160%), and
increased hepatic cholesterol accumulation (þ88%).
Importantly, rimonabant markedly lowered athero-
sclerotic lesion size (¡64%), which coincided with
decreased lesion severity (28% vs. 56% severe le-
sions) and which strongly correlated with non-HDL-
C exposure (R2 ¼ 0.60). Taken together, inhibition
of the endocannabinoid system potently reverses*For correspondence: Patrick C. N. Rensen, p.c.n.rensen@lumc.nl.
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the absence of obesity.
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The majority of CVD is caused by atherosclerosis
driven by inflammatory processes and dyslipidemia (1),
which is characterized by high plasma non-HDL-C, high
plasma triglyceride (TG), and low plasma HDL-C levels.
Therefore, reverting dyslipidemia, and especially
reducing non-HDL-C, is of key importance for
reducing atherosclerosis and therefore the prevention
of atherosclerotic CVD (2).
A potential strategy to revert dyslipidemia is stimu-
lation of adipose tissue thermogenesis. Brown adipose
tissue (BAT) converts energy stored in their intracel-
lular lipid droplets into heat in the presence of
uncoupling protein 1 (UCP1), which uncouples the
mitochondrial electron transport chain from ATP
synthesis (3). In addition, white adipose tissue (WAT)
may acquire a more brown-like phenotype, a process
referred to as browning that yields so-called beige ad-
ipocytes scattered between white adipocytes (4). To
replenish internal lipid stores, thermogenic adipocytes
selectively take up FAs after LPL-mediated liberation
from triglyceride-rich lipoproteins (TRLs), thereby
accelerating the generation and hepatic clearance of
cholesterol-enriched TRL remnants (5, 6). During
lipolysis, TRL surface remnants are transferred to
HDL, which increases HDL-C levels and reverse
cholesterol transport (RCT) (7). Taken together, activa-
tion of BAT thermogenesis is capable of loweringJ. Lipid Res. (2021) 62 100070 1
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plasma TG and non-HDL-C levels while increasing
plasma HDL-C levels, thereby attenuating dyslipidemia
and protecting against atherosclerosis (8).
The main physiological activator of BAT thermogen-
esis is cold exposure, which results in the release of
norepinephrine from sympathetic nerve endings within
the tissue. Norepinephrine binds to β-adrenergic re-
ceptors onbrownadipocytes, thereby activating adenylyl
cyclase leading to cAMP production, intracellular lipol-
ysis, and ultimately thermogenesis. This cascade is
inhibited by cannabinoid type 1 receptor (CB1R)
signaling, which prevents cAMP production through
inhibition of adenylyl cyclase activity (9, 10). β-adrenergic
stimulation elicits the production of endocannabinoids,
the endogenous ligands for the CB1R, by thermogenic
adipose tissue, which may act as a negative feedback
mechanism to dampen thermogenesis (11). Indeed, we
and others have previously shown that pharmacological
blockadeof theCB1R invivo increases thermogenicBAT
activity (12) and consequently attenuates dyslipidemia
and protects from diet-induced obesity in mice (12–14).
Moreover, CB1R inverse agonism has been shown to
prevent atherosclerosis in ApoE−/− and LDL receptor
(LDLr−/−) mice (15, 16). However, as these mice lack an
intact ApoE-LDLr pathway, these models largely pre-
clude studying the antiatherogenic effects in the context
of improvements in lipoprotein metabolism (5).
Attempts have been made to improve car-
diometabolic health by inverse CB1R agonism using
rimonabant in humans (17–19) and the early Rimona-
bant in Obesity-Lipids trial showed that rimonabant
improved atherogenic dyslipidemia (20). Unfortunately,
production and sale were suspended after being on the
market for 2 years because of risk of serious psychiatric
side effects (21). Interest in the endocannabinoid system
as a therapeutic target dropped but recently gained
new attention after the development of peripherally
restricted CB1R antagonists (22) and endocannabinoid
synthesis inhibitors (10, 23, 24). Therefore, in the cur-
rent study, we continued studying the cardiometabolic
benefits of CB1R modulation and aimed to investigate
whether CB1R inverse agonism attenuates atheroscle-
rosis development through reversal of dyslipidemia
using APOE*3-Leiden.CETP (E3L.CETP) mice, a well-
established mouse model for human-like atheroscle-
rosis development with an intact ApoE-LDLr pathway.MATERIALS AND METHODS
Animals and diet
Homozygous human cholesteryl ester transfer protein
(CETP) transgenic mice were crossbred with hemizygous
APOE*3-Leiden mice to generate E3L.CETP mice as detailed
earlier (25). About 10–14-week-old mice were fed a Western-
type diet containing 16% fat (15% cocoa butter and 1% corn
oil) and 0.10% (experiment 1) or 0.15% cholesterol (experiment
2 and 3) (Altromin C 1000 mod. #100184 and #100185,2 J. Lipid Res. (2021) 62 100070respectively) for 3 weeks. Following this run-in period, in each
experiment, mice were divided into two groups that were
balanced for age, body weight, body composition, plasma TG
levels, and plasma total cholesterol (TC) levels. Subsequently,
mice were fed the respective Western-type diet supplemented
with or without 20 mg⋅kg body weight−1 day−1 (0.0167%, w⋅w−1)
rimonabant for 4 weeks (n = 7 with rimonabant, n = 8 without
rimonabant, experiment 1; n = 8 per group, experiment 3) or
20 weeks (n = 15 per group, experiment 2). In experiment 2,
one control mouse, because of malocclusion, and two
rimonabant-treated mice, because of progressive ulcerative
dermatitis, were excluded from all analyses. Mice were
housed in conventional cages with a 12:12 h light-dark cycle
with ad libitum access to food and water. All mouse experi-
ments were performed in accordance with the Institute for
Laboratory Animal Research Guide for the Care and Use of
Laboratory Animals and had received approval from the
Ethical Review Board for Animal Experimentation of the
Leiden University Medical Center, Leiden, the Netherlands.Body weight, body composition, and food intake
Every 4 weeks (experiment 1 and 2), the mice were weighed,
and body composition was determined using an EchoMRI-100
(EchoMRI). Food intake was measured by weighing and
divided by the number of mice in each cage (n = 1 per cage,
experiment 1; n = 4 per cage, experiment 2) to express the
data as food intake in gram per mouse per day.Plasma lipid levels
Every 4 weeks (experiment 1 and 2), mice were fasted for
4 h (9:00 AM to 1:00 PM clock time, corresponding to Zeitgeber
time [ZT] 2–6), and subsequently, blood was drawn from the
tail vein in capillaries coated with paraoxon to prevent
ongoing lipolysis. Blood plasma obtained after centrifugation
was used to determine plasma TG and TC levels using enzy-
matic kits (10166588130 and 11489232216, respectively; Roche
Diagnostics). Plasma HDL-C levels were determined in the
supernatant after precipitation of ApoB-containing lipopro-
teins from plasma by addition of 20% polyethylene glycol
6000 (Sigma-Aldrich) in 200 mM glycine buffer (pH 10). From
the TC and HDL-C levels, the non-HDL-C levels were
calculated.Plasma levels of adhesion molecules
In 4-h fasted plasma samples collected as described above
from 20-week treated mice (experiment 2), levels of intercel-
lular adhesion molecule-1 and vascular cell adhesion
molecule-1 were determined by ELISA using the manufac-
turer's protocols (MIC100 and MVC00, respectively; R&D
Systems).Indirect calorimetry
In the fourth week of short-term intervention (experiment
1), mice were single housed in calorimetric cages (Promethion
Line; Sable Systems International) to measure O2 consump-
tion and CO2 production. After 5 days acclimatization, O2
consumption and CO2 production were measured at 5-min
intervals for 2 consecutive days, from which the average en-
ergy expenditure, respiratory exchange ratio, carbohydrate
oxidation rate, and FA oxidation rate were calculated (5). In
the fourth week of experiment 2, mice were single housed,
and feces samples were collected for determining bile acid
(BA) levels as described below.BAT and WAT histology
At the end of the 4-week intervention period (experiment
1), mice were euthanized by CO2 inhalation, collected organs
were weighed, and interscapular BAT (iBAT), gonadal WAT
(gWAT), and subcutaneous WAT (sWAT) samples were
fixated in 4% paraformaldehyde, dehydrated, and embedded
in paraffin. Cross-sections of 5 μm were deparaffinized and
treated with 0.3% H2O2 in 40% CH3OH to quench endogenous
peroxidases (30 min). Sections were immersed in 10 mM cit-
rate buffer at pH 6.0 (10 min, 97◦C), blocked with 5% normal
BSA in PBS (30 min, room temperature), and incubated
overnight at 4◦C with rabbit polyclonal anti-UCP1 (U6382;
Sigma-Aldrich; 1:2000 in 1% BSA). After incubation, sections
were incubated with HRP-labeled α-rabbit secondary anti-
body (K4003; DAKO EnVision™; 30 min, room temperature),
which were then visualized by NovaRED™ HRP substrate
(Vector Labs; 7 min, room temperature). Sections were coun-
terstained with Mayers Hematoxylin (1.09249; Merck; 1:4 in
H2O, 45 s, room temperature). Expression of UCP1 was
quantified in iBAT and sWAT using ImageJ software (Na-
tional Institutes of Health; version 1.52a), and stained area was
expressed as a relative percentage of total lean area. Also
using this software, the average adipocyte size was determined
in gWAT and sWAT. Because of technical problems n = 6 per
group remained for histological analysis.RCT assay
After 2 weeks of treatment with and without rimonabant
(experiment 3), in vivo RCT was determined using a proced-
ure originally developed by Zhang et al. (26). Four days before
isolating peritoneal macrophages, donor female APOE*3-
Leiden mice received an intraperitoneal injection with 1 ml
3% Brewer's thyoglycollate medium (B2551; Merck). To load
the recruited peritoneal macrophages with cholesterol, these
donor mice received an intraperitoneal injection with 100 μg
acetylated LDL and 125 μCi [1,2–3H(N)]-cholesterol
(NET139001MC; PerkinElmer) 1 h before isolation by perito-
neal lavage with 10 ml warm PBS. Macrophages were washed
and resuspended in RPMI-1640 (30-2001; ATCC), and recipient
mice were intraperitoneally injected with 2 ×⋅105 macro-
phages and single housed for 72 h during which feces was
collected. Feces samples (30–50 mg) were dissolved overnight
at 55◦C in 1 ml Tissue Solubilizer (Amersham Biosciences,
Roosendaal, the Netherlands) with 200 μl 30% H2O2 after
which 3H activity was determined in a liquid scintillation
counter.Hepatic VLDL-TG and VLDL-ApoB production rate
To quantify VLDL production in vivo, after 4 weeks of
treatment (experiment 3), mice were fasted for 4 h (07:00 AM
to 11:00 AM clock time, corresponding to ZT 0–4) and anes-
thesized by a mixture of acepromazin, midazolam, and fen-
tanyl (6.3, 6.3, and 0.3 mg/kg, respectively, intraperitoneally,
followed by 31.3, 31.3, and 1.6 μg, respectively, subcutaneously
every 45 min). Mice were subsequently intravenously injected
with 10 μCi Tran[35S] label (IS-103; Hartmann Analytic) to label
newly synthesized ApoB. About 30 min later, mice were
intravenously injected with 5 μl/g body weight 10% Triton
WR-1339 (T0307; Sigma-Aldrich) in PBS to block VLDL-TG
clearance. Just prior to, and 15, 30, 60, and 90 min afterinjection with Triton WR-1339, blood was drawn from the tail
vein, and plasma TG was determined as described above.
After 120 min, mice were exsanguinated via the retroorbital
sinus, and VLDL was isolated from serum after density
gradient ultracentrifugation at d < 1.006 g/ml (27) by aspira-
tion, in which 35S activity was determined using a liquid
scintillation counter, and TG and TC was determined as
described above.Plasma decay and organ uptake of VLDL-like
particles
At the end of the 20-week intervention period (experi-
ment 2), mice were fasted for 4 h (9:00 AM to 1:00 PM clock
time, corresponding to ZT 2–6), blood was drawn as
described above, and subsequently, mice were intrave-
nously injected with glycerol tri[3H]oleate and [14C]choles-
teryl oleate double-labeled VLDL-like particles (1.0 mg TG
in 200 μl PBS per mouse) as described earlier (28). Blood
was drawn from the tail vein at 2, 5, 10, and 15 min after
injection to determine the plasma decay of both radiola-
bels. Then, mice were euthanized by CO2 inhalation, heart
puncture plasma was collected, and mice were perfused
with ice-cold PBS to remove blood from organs. Collected
organs were weighed, and pieces were dissolved overnight
at 55◦C in Tissue Solubilizer (Amersham Biosciences, Roo-
sendaal, the Netherlands), and 3H and 14C activity were
determined in a liquid scintillation counter. Part of the
liver was snap-frozen in liquid nitrogen and stored
at −80◦C for determining hepatic lipid content and mRNA
expression as described below. The hearts were fixated in
4% paraformaldehyde, dehydrated, and embedded in
paraffin for atherosclerosis quantification, as also
described below.Hepatic lipid content
Liver lipids were extracted according to a modified pro-
tocol of Bligh and Dyer (29). Briefly, liver samples obtained
from experiment 2 (approximately 50 mg) were cut and ho-
mogenized in 10 μl CH3OH per mg tissue. Lipids were
extracted by addition of 1,800 μl CH3OH:CHCl3 (1:3 v⋅v−1) to
45 μl homogenate, followed by vigorous vortexing and
centrifugation (15 min; 20,000 g). The organic phase was dried
under a gentle stream of nitrogen and dissolved in 100 μl 2%
Triton X-100 in CHCl3 and after another drying step dissolved
in 100 μl H2O. TG and TC levels were determined as described
above and expressed as nmol⋅mg−1 protein, for which protein
concentration was determined using the Pierce™ bicincho-
ninic acid assay kit (23225; ThermoFisher).Hepatic gene expression analysis
Total RNA was extracted from liver samples (approxi-
mately 30–50 mg) obtained from experiment 2 using TriPure
RNA Isolation Reagent (Roche Diagnostics) according to the
manufacturer's protocol. RNA concentration was determined
by NanoDrop (Thermo Scientific), and 1 μg cDNA was syn-
thesized for each sample using Moloney Murine Leukemia
Virus Reverse Transcriptase (Promega) according to the
manufacturer's protocol. Quantitative real-time PCR was
performed using GoTaq® qPCR Master Mix (A6002; Prom-
ega) with a Bio-Rad CFX96 Touch™ Real-Time PCR Detec-
tion System. mRNA expression levels were normalized to
Rplp0 mRNA expression and expressed as fold change usingCB1R inhibition attenuates atherosclerosis 3




























Abcg5, ATP-binding cassette subfamily G member 5; Acaca, acetyl-CoA carboxylase 1; Bsep, bile salt export pump; Cidea,
cell death-inducing DFFA-like effector A; Cyp27a1, sterol 27-hydroxylase; Cyp7a1, cholesterol 7 alpha-hydroxylase; Cyp7b1,
oxysterol and steroid 7-alpha-hydroxylase; Cyp8b1, sterol 12-alpha-hydroxylase; Fasn, fatty acid synthase; Hmgcr, HMG-CoA
reductase; Il1b, interleukin 1 beta; Il6, interleukin 6; Ldlr, low density lipoprotein receptor; Mttp, microsomal triglyceride
transfer protein; Ppargc1a, peroxisome proliferative-activated receptor gamma coactivator 1 alpha; Prdm16, PR/SET domain
16; Rplp0, ribosomal protein lateral stalk subunit P0; Scd1, stearoyl-CoA desaturase 1; Tgfb1, transforming growth factor beta
1; Tnfa, tumor necrosis factor alpha.the 2−ΔΔCT method. A list of used primer sequences is pre-
sented in Table 1.Plasma and fecal BA levels
In heart puncture plasma and feces samples, BA levels were
measured by LC/MS. Full details on chemicals, instrumenta-
tion, and method validation are provided in the supplemental
data section. Briefly, 100 μl heart puncture plasma was added
to 10 μl internal standard solution (500 ng/ml) and 290 μl
CH3OH. Samples were vortexed (5 s) and stored at −20◦C for
20 min. Then, samples were centrifuged (10 min; 18,213 g; 4◦C),
supernatant was dried under a gentle stream of nitrogen, and
reconstituted by addition of 40 μl CH3OH followed by vor-
texing (5 s) and sonication (VWR USC 300 THD/HF; 1 min;
maximum power; 22◦C). About 60 μl H2O was added, and
samples were vortexed (5 s) and centrifuged (10 min; 18,213 g;
4◦C). About 80 μl supernatant was transferred to glass micro
vial inserts, and samples were placed in the autosampler.
For feces samples, 75% CH3OH was added to approxi-
mately 40 mg sample to obtain a final concentration of
40 mg/ml. Samples were homogenized using a Next Advance
Bullet Blender (BBx24B-CE; maximum speed; 10 min) after
addition of three 3.2 mm stainless steel beads and a mixture of
0.9–2.0 mm stainless steel beads (approximately equal volume
to feces sample). Subsequently, samples were vortexed (5 s)
and 10 times diluted in 75% CH3OH. Samples were then vor-
texed (5 s), sonicated (1 min; maximum power, 22◦C), vortexed
(5 s), and centrifuged (5 min; 18,213 g; 20◦C), after which 10 μl
supernatant was transferred to glass micro vial inserts, and
10 μl internal standard solution (500 ng/ml) and 80 μl 50%4 J. Lipid Res. (2021) 62 100070CH3OH was added. Samples were then vortexed (5 s) and
placed in the autosampler.Atherosclerosis quantification
Paraffin-embedded hearts were cross-sectioned (5 μm)
throughout the aortic root area. Cross-sections were stained
with hematoxylin-phloxine-saffron to determine lesion area
as described previously (30). Lesions were categorized for
lesion severity according to the guidelines of the American
Heart Association adapted for mice (31) and categorized as
mild lesions (type I–III) and severe lesions (type IV–V). Mac-
rophages and smooth muscle cell actin were double stained
using rat monoclonal anti-MAC-3 antibody (550292; BD
Pharmingen) with Vector ImmPRESS® anti-rat (MP-7444;
Vector Laboratories), and mouse monoclonal antiactin anti-
body (M0851; Dako) with DAKO EnVision™ anti-mouse,
which were visualized with Vina Green (BRR807AH; Bio-
care) and 3,3′ diaminobenzidine (K3468; Dako), respectively.
Collagen was stained with Sirius Red (1A280; Chroma). Lesion
area and macrophage, smooth muscle cell, and collagen con-
tent were determined using ImageJ software (National In-
stitutes of Health; version 1.52a).Statistical methods
Comparisons between groups were made by two-sided in-
dependent sample t-tests. Pearson product-moment correla-
tion coefficients were determined to assess linear correlations
between variables. P values less than 0.05 were considered
statistically significant.
RESULTS
CB1R inverse agonism lowers plasma TG and TC
levels and stimulates WAT browning
In the first experiment, hyperlipidemic E3L.CETP
mice were fed with or without supplementation of the
CB1R inverse agonist rimonabant for 4 weeks to
investigate the short-term effects on dyslipidemia, en-
ergy expenditure, and adipose tissue thermogenesis in
an obesity-independent context. Rimonabant treatment
decreased body weight throughout the intervention
(Fig. 1A) by selectively lowering fat mass as compared
with control (1.7 vs. 3.2 g after 4 weeks of treatment;
Fig. 1B). Food intake was reduced during the first 2 days
of rimonabant treatment but normalized thereafter
(Fig. 1C). Total energy expenditure as measured by in-
direct calorimetry did not differ between rimonabant
and control (Fig. 1D, supplemental Fig. S1A), but theFig. 1. Rimonabant lowers plasma triglyceride and total cholester
APOE*3-Leiden.CETP mice were fed a Western-type diet with or w
verse agonist rimonabant for 4 weeks. A: Body weight was monitore
treatment. C: Food intake was measured throughout the entire inter
calorimetric cages to determine O2 consumption and CO2 productio
ratio, (F) FA oxidation rate, and (G) carbohydrate oxidation rate
triglycerides and total cholesterol were determined in 4-h fasted b
WAT (sWAT) and interscapular brown adipose tissue (iBAT) were c
1 (UCP1). Data are presented as mean ± SEM and individual data prespiratory exchange ratio was lower during the light
phase (Fig. 1E) in rimonabant-treated mice because of
increased FA oxidation at the expense of glucose
oxidation (Fig. 1F–G). Without correction for lean mass,
the increase in FA oxidation did not reach statistical
significance (supplemental Fig. S1B, C). After 4 weeks of
treatment, rimonabant treatment decreased plasma TG
(−49%) and TC levels (−31%) (Fig. 1H). Liver weight was
slightly increased in rimonabant-treated mice (+14%),
and in concordance with the lowered fat mass, rimo-
nabant reduced gWAT weight (−58%) and sWAT
weight (−43%) (supplemental Fig. S1D) and reduced the
average sWAT adipocyte size (supplemental Fig. S1E).
Whilst gene expression levels of Ucp1 and the browning
markers Ppargc1a, Cidea, and Prdm16 were not altered
(supplemental Fig. S1F), rimonabant increased the UCP1
positive area in sWAT (+4-fold; Fig. 1I, J). UCP1 in iBAT
was not changed (Fig. 1I, K). Altogether these data showol levels and stimulates white adipose tissue browning. Female
ithout supplementation of the cannabinoid type 1 receptor in-
d weekly. B: Body composition was determined after 4 weeks of
vention period. In the fourth week, mice were single housed in
n from which (D) energy expenditure, (E) respiratory exchange
were calculated and expressed per gram lean mass. H: Plasma
lood plasma samples. Mice were sacrificed, and subcutaneous
ollected, (I) stained, and (J, K) quantified for uncoupling protein
oints. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Fig. 2. Rimonabant improves dyslipidemia as related to increased triglyceride (TG)-rich lipoprotein turnover. Female APOE*3-
Leiden.CETP mice were fed a Western-type diet with or without rimonabant for 20 weeks. A: Body weight, (B) food intake, as
well as plasma levels of (C) triglycerides, (D) total cholesterol, (E) non-HDL-C, and (F) HDL-C were monitored throughout the
intervention period. Plasma clearance and organ uptake of (G–I) TG-derived 3H-labeled FAs and (J–L) 14C-labeled cholesteryl ester
from recombinant TG-rich lipoproteins were determined and expressed per gram gonadal WAT (gWAT) and subcutaneous WAT
(sWAT), muscle, interscapular brown adipose tissue (iBAT), and subscapular brown adipose tissue (sBAT), liver, perivascular adipose
tissue (pVAT), and spleen. Liver samples were collected to assess (M) relative mRNA expression levels of angiopoietin-like protein
(Angptl) 3, 4, and 8 and of Lpl. Data are presented as mean ± SEM and individual data points. *P < 0.05, **P < 0.01, and ***P < 0.001.
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that in lean E3L.CETP mice, rimonabant attenuates
dyslipidemia, induces a shift from glucose to FA
oxidation, and stimulates WAT browning.
CB1R inverse agonism improves dyslipidemia as
related to increased VLDL turnover and reduced
hepatic VLDL production
To investigate the long-term effects of CB1R inverse
agonism on lipoprotein metabolism, we next treated
E3L.CETP mice with or without rimonabant for a
duration of 20 weeks. Throughout the intervention
period, rimonabant slightly but consistently reduced
body weight (Fig. 2A) and food intake (Fig. 2B).
Consistent with the short-term study, rimonabant
reduced plasma TG, which persisted throughout the
entire intervention period (−62% to −46%; Fig. 2C).
Rimonabant treatment modestly decreased plasma TC,
which reached statistical significance only after
16 weeks of treatment (−18%; Fig. 2D). This was due to a
lowering of non-HDL-C, reaching significance after 12
and 16 weeks of treatment (−25% and −32%, respec-
tively; Fig. 2E), whereas HDL-C levels were increased
throughout the entire intervention period (+46%
to +62%; Fig. 2F). Plasma glucose after 20 weeks of
treatment was not affected by rimonabant treatment in
these lean mice (data not shown).
To elucidate whether increased lipolytic processing
and plasma clearance of VLDL explains the reduction
in plasma lipids within non-HDL, we next used VLDL-
like particles containing glycerol tri[3H]oleate and [14C]
cholesteryl oleate to investigate plasma clearance and
organ uptake of TG-derived FA and VLDL core rem-
nants, respectively. Compared with control, rimonabant
treatment accelerated the clearance of glycerol tri[3H]
oleate (Fig. 2G), which was accompanied by increased
[3H]oleate uptake by sWAT (1.8% vs. 1.0%/g organ;
Fig. 2H) and a nonsignificantly increased uptake by the
various BAT depots (iBAT, 24% vs.15%/g organ; sub-
scapular BAT, 21% versus 12%/g organ; perivascular
adipose tissue, 32% vs. 20%/g organ; Fig. 2I). The
clearance of [14C]cholesteryl oleate tended to be accel-
erated (Fig. 2J), with higher uptake by gWAT (0.15% vs.
0.09%), sWAT (0.26% vs. 0.16%), and perivascular adi-
pose tissue (3.63% vs. 1.15%) (Fig. 2K, L). When data are
expressed per whole organ, rimonabant increased both
the uptake of [3H]oleate and [14C]cholesteryl oleate in
subscapular BAT (0.59% vs. 0.34% and 0.06% vs. 0.03%,
respectively; supplemental Fig. S2E, F). Consistent with
increased lipolytic processing of plasma TG, rimona-
bant decreased hepatic gene expression of
angiopoietin-like protein (Angptl) 4 (−31%) and Angptl8
(−53%), known for their role as modulators of LPL
activity, without affecting Angptl3 expression, and
increased Lpl expression 3-fold (Fig. 2M). Similar to the
short-term study, rimonabant increased liver weight as
compared with control (+22%) and lowered gWAT
weight (−54%) as well as sWAT weight (−34%)
(supplemental Fig. S2G).As plasma TG levels are determined by both VLDL-
TG clearance and production, we next investigated the
in vivo VLDL-TG production rate as well as VLDL-
ApoB production in an additional group of E3L.CETP
mice treated with or without rimonabant for a duration
of 4 weeks. Rimonabant strongly decreased VLDL-TG
production (−52%) as well as VLDL-ApoB production
(−55%) (Fig. 3A, B), without affecting TG/ApoB and
TC/ApoB ratio (Fig. 3C, D). These changes were neither
accompanied by significant reductions in the hepatic
expression of lipogenic genes, such as Fasn, Scd1, and
Acaca, nor a reduction in expression of the cholesterol
synthesis gene Hmgcr in the 20-week treated mice, but
correspondingly, rimonabant reduced the hepatic
expression of Apob (−20%) and Mttp (−31%), both
involved in VLDL assembly (Fig. 3E).
From these data, we conclude that rimonabant im-
proves dyslipidemia through a combination of
decreased hepatic VLDL particle production and
increased VLDL turnover as a result of increased
lipolytic activity in adipose tissue.
CB1R inverse agonism influences BA metabolism
and hepatic cholesterol
We previously observed that activation of thermo-
genic tissues lowers TC by increasing the total delivery
of cholesterol from peripheral tissues to the liver (5, 7)
coupled to increased hepatic BA synthesis. On the long
term, this leads to increased plasma BA levels with
negative feedback in the liver on expression of genes
involved in BA synthesis, resulting in hepatic choles-
terol accumulation (5, 32). Therefore, we next assessed
the effects of rimonabant on fecal and plasma BAs, as
well as on hepatic lipids in the E3L.CETP mice that were
treated with or without rimonabant for 20 weeks.
Although rimonabant treatment did not alter total
fecal BA excretion (supplemental Fig. S2A–D,
supplemental Table S1), it markedly increased total BAs
in plasma (+160%; Fig. 4A and supplemental Table S1),
which was explained by increased levels of both cholic
acid-derived BAs (+196%; Fig. 4B) and chenodeox-
ycholic acid-derived BAs (+126%; Fig. 4C). Consistently,
rimonabant lowered the hepatic expression of Cyp8b1
(−29%) and Cyp27a1 (−33%), which are involved in the
classical and alternative BA synthesis pathway, respec-
tively (Fig. 4E). Rimonabant also reduced the hepatic
expression of Bsep, involved in the excretion of BAs
(−21%; Fig. 4E).
Probably because of impaired hepatic synthesis of
BAs from cholesterol, rimonabant highly increased
hepatic TC content (+88%), whereas slightly decreasing
hepatic TG content (−10%) (Fig. 4F), which is consistent
with a nonsignificant decrease of hepatic Ldlr expres-
sion (−22%, P = 0.06; Fig. 4G). Hepatic cholesterol
accumulation was accompanied by increased hepatic
gene expression of the proinflammatory cytokine Tnfa
(+109%) and the profibrotic cytokine Tgfb1 (+32%)
(Fig. 4G) and by an increased plasma level ofCB1R inhibition attenuates atherosclerosis 7
Fig. 3. Rimonabant lowers hepatic VLDL-triglyceride (TG) and VLDL-ApoB production. Female APOE*3-Leiden.CETP mice were
fed a Western-type diet with or without rimonabant for 4 weeks. Mice received intravenous injection with Tran[35S] label followed
by Triton WR1339, and TG levels were determined in plasma samples drawn at the indicated time points, which were (A) plotted as
the increase in TG to baseline, from which VLDL-TG production rate was determined by linear regression. By measuring 35S in
isolated VLDL (B), ApoB production rate was determined. C, D: VLDL lipid content was assessed and expressed as a ratio of ApoB. In
20-week treated mice, liver samples were collected to assess (E) relative mRNA expression levels of lipogenic (Fasn, Scd1, and Acaca)
and cholesterogenic (Hmgcr) genes, as well as genes involved in VLDL assembly (Apob and Mttp). Data are presented as mean ± SEM
and individual data points. *P < 0.05 and ***P < 0.001. Acaca, acetyl-CoA carboxylase 1; Fasn, fatty acid synthase; Hmgcr, HMG-CoA
reductase; Mttp, microsomal triglyceride transfer protein; Scd1, stearoyl-CoA desaturase 1; TC, total cholesterol.intercellular adhesion molecule-1 (+30%) but not
vascular cell adhesion molecule-1 (Fig. 4H). To deter-
mine the impact of impaired BA synthesis, we next
determined the rate of RCT by intraperitoneal injec-
tion of [3H]cholesterol-laden macrophages in E3L.CETP
mice treated with or without rimonabant for a duration
of 2 weeks and found that rimonabant decreased fecal
3H excretion (−30%; Fig. 4I). To conclude, in concor-
dance with increased total delivery of cholesterol to-
ward the liver combined with increased BAs in plasma
and thus likely also in liver, prolonged treatment with
rimonabant thus resulted in downregulation of hepatic
BA synthesis, hepatic cholesterol accumulation, and
reduced RCT.
CB1R inverse agonism attenuates atherosclerotic
plaque development
Next, to evaluate whether rimonabant attenuates
atherogenesis in our mouse model, we quantified the
atherosclerotic lesion area in the aortic root region of
the hearts after 20 weeks of treatment. Atheroscle-
rotic lesion area was markedly decreased by rimo-
nabant (−64%; Fig. 5A–C) and showed a strong
correlation with non-HDL-C exposure (control R2 =
0.54; β = 0.08, P < 0.01; rimonabant R2 = 0.41, β = 0.05,8 J. Lipid Res. (2021) 62 100070P < 0.05; Fig. 5D). Correspondingly, rimonabant
decreased the overall lesion severity as compared
with control, as indicated by a lower percentage of
severe lesions (28% vs. 56%) and a higher percentage
of mild lesions (72% vs. 44%) (Fig. 5E). Atherosclerotic
lesion composition was determined in all lesions and
within type III lesions only to correct for natural
compositional discrepancies between the various
lesion severity types. However, the relative content of
collagen, smooth muscle cells, and macrophages was
not altered by rimonabant either in all lesions
(supplemental Fig. S2H–J) or in type III lesions only
(Fig. 5F–J).DISCUSSION
Since CB1R inverse agonism by rimonabant im-
proves atherogenic dyslipidemia in mice (12–14) and
humans (20), in the current study, we aimed to
investigate whether rimonabant attenuates athero-
sclerosis development using hyperlipidemic
E3L.CETP mice, a well-established mouse model for
human-like lipoprotein metabolism because of an
intact ApoE-LDLr pathway. We demonstrated that
rimonabant reversed dyslipidemia by decreasing
Fig. 4. Rimonabant influences bile acid (BA) metabolism and hepatic cholesterol. Female APOE*3-Leiden.CETP mice were fed a
Western-type diet with or without rimonabant for 20 weeks. Mice were sacrificed, and heart puncture samples were collected to
determine the plasma (A) total BAs, (B) cholic acid (CA)-derived BAs, and (C) chenodeoxycholic acid (CDCA)-derived BAs, as well as
(D) secondary BAs as a percentage of total. Liver samples were collected to assess (E) relative mRNA expression levels of genes
involved in the classical BA synthesis pathway (Cyp7a1 and Cyp8b1), the alternative BA synthesis pathway (Cyp27a1 and Cyp7b1), and the
excretion of neutral sterols and cholesterol (Abcg5 and Bsep), to assess (F) hepatic total cholesterol and TG content and to assess (G)
expression of Ldlr and of various proinflammatory and profibrotic markers. H: In blood plasma collected after 20 weeks of treat-
ment, plasma levels of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1) were determined. I:
In an additional group of female APOE*3-Leiden.CETP mice fed a Western-type diet with or without rimonabant for 2 weeks, mice
received intraperitoneal injection with [3H]cholesterol-laden macrophages, and total fecal excretion of the radiolabel was deter-
mined during the following 72 h. Data are presented as mean ± SEM and individual data points. *P < 0.05 and ***P < 0.001. Abcg5,
ATP-binding cassette subfamily G member 5; Bsep, bile salt export pump; Cyp27a1, sterol 27-hydroxylase; Cyp7a1, cholesterol 7 alpha-
hydroxylase; Cyp7b1, oxysterol and steroid 7-alpha-hydroxylase; Cyp8b1, sterol 12-alpha-hydroxylase; Il6, interleukin 6; Il1b, interleukin
1 beta; Ldlr, low density lipoprotein receptor; Tgfb1, transforming growth factor beta 1; Tnfa, tumor necrosis factor alpha.hepatic VLDL particle production and increasing
VLDL turnover related to browning of WAT,
together resulting in the prevention of atheroscle-
rosis development.
We observed that CB1R inverse agonism potently
lowers plasma TG levels, which was accompanied by
accelerated plasma TG clearance as a result of
increased TG-derived FA uptake by WAT, and a
nonsignificantly increased FA uptake by BAT. These
effects are consistent with enhanced thermogenic ac-
tivity in adipose tissue and seem to be explained by
pronounced browning of WAT related to a highly
increased UCP-1 expression, rather than moreactive classical BAT. In a previous study in which we
investigated the effect of rimonabant in the context of
high-fat diet-induced obesity, we observed that rimo-
nabant did increase the uptake of TG-derived FA by
BAT (12). The seeming discrepancy between these
studies is likely explained by the difference in dietary
fat, which has recently been shown to acutely increase
circulating endocannabinoid levels (33, 34). As higher
endocannabinoid levels will reduce BAT activity by
activation of CBRs, blocking the actions of endo-
cannabinoids by rimonabant will potently restore BAT
activity in the context of high-fat diet feeding. Indeed,
the baseline FA uptake by BAT of E3L.CETP mice fed aCB1R inhibition attenuates atherosclerosis 9
Fig. 5. Rimonabant attenuates atherosclerotic plaque development. Female Western-type diet-fed APOE*3-Leiden.CETP mice
were fed with or without supplementation of the cannabinoid type 1 receptor inverse agonist rimonabant for 20 weeks. Mice were
sacrificed, and hearts were collected. A: Cross-sections of the aortic root area were stained with hematoxylin-phloxine-saffron, and
pictures of representative cross-sections are shown. B: Atherosclerotic lesion area was determined and is expressed as a function of
distance from the appearance of open aortic valves, from which (C) the mean atherosclerotic lesion area was calculated. D: The
square root of the mean atherosclerotic lesion area from C was plotted against the total non-HDL-C exposure. E: Lesions were
categorized according to lesion severity and expressed as a percentage of total lesions. G: The smooth muscle cell (brown staining),
(H) macrophage (green staining), and (J) collagen (red staining) area were measured within type III lesions, and (F, I) pictures of
representative cross-sections are shown. Data are presented as mean ± SEM and individual data points. *P < 0.05 and **P < 0.01.high-fat diet (2%–5%/g organ) (12) was much lower
than observed in the present study (10%–15%/g organ).
This may also be relevant for humans as obese in-
dividuals have increased endocannabinoid levels when
compared with lean individuals (35). Rimonabant not
only increased VLDL turnover but also robustly
decreased the production of VLDL-TG. Since this ef-
fect was paralleled by a similar decrease in VLDL-ApoB
production, and each VLDL contains a single ApoB
molecule, rimonabant apparently decreases VLDL
particle production rather than lipidation of ApoB.10 J. Lipid Res. (2021) 62 100070Altogether in lean, Western-type diet-fed mice as used
in the current study, CB1R inverse agonism decreases
plasma TG levels and strongly attenuates atheroscle-
rotic plaque development.
Besides lowering plasma TG, rimonabant decreased
plasma non-HDL-C, increased plasma BAs, and
increased hepatic cholesterol. These effects are consis-
tent with previous reports that β3-adrenergic receptor
agonism stimulates VLDL lipolysis accompanied by an
enhanced flux of cholesterol-enriched VLDL remnants
to the liver, which is efficiently coupled to higher
production of BAs (32, 36). This results in higher fecal
sterol output on the short term (36) but decreases fecal
output and increases plasma BA levels on the long term
(32). While increased systemic BA levels may be bene-
ficial in further inducing thermogenesis (37) and likely
related to the reduction in VLDL synthesis (38), they
also provide negative feedback on hepatic BA synthesis
(39). Indeed, rimonabant decreased hepatic expression
of genes involved in the classical and alternative BA
synthesis pathways, similar as we previously observed
after prolonged β3-adrenergic receptor agonism (32). In
line with this, RCT was strongly attenuated in
rimonabant-treated mice. Whether the accumulation of
BAs in plasma is caused by enhanced intestinal reup-
take and/or by delayed BA clearance by the liver re-
mains a topic for future studies. However, to prevent
undesired hepatic cholesterol accumulation coupled to
downregulation of hepatic BA synthesis, it would be
interesting to investigate combined rimonabant treat-
ment with BA sequestrants, which, as we previously
demonstrated, largely increases BA excretion and
effectively prevents hepatic cholesterol accumulation
upon β3-adrenergic receptor agonism (32).
The close resemblance between the effects of CB1R
inverse agonism and β3-adrenergic receptor agonism
on hepatic cholesterol and BA metabolism may not be
surprising as the CB1R and the β3-adrenergic receptor
have closely coupled signaling pathways. To be specific,
β3-adrenergic signaling promotes intracellular adenylyl
cyclase activity, whereas CB1R signaling inhibits it (9). In
fact, others have recently suggested that the endo-
cannabinoid system acts as a negative feedback mech-
anism to dampen β-adrenergic signaling in the adipose
tissues (11). It would thus be interesting to investigate
whether β3-adrenergic agonism may synergize with
CB1R inverse agonism to further attenuate dyslipide-
mia and atherosclerosis development.
Finally, rimonabant strongly reduced atherosclerotic
plaque development, with a strong correlation between
non-HDL-C exposure and atherosclerotic lesion size.
This is similar to what we previously showed for, for
example, β3-adrenergic agonism (5) and anacetrapib
(40), and is fully consistent with the causal role of non-
HDL-C in atherosclerosis progression (2). We thus
interpret that rimonabant attenuates atherosclerosis by
at least two ways, namely by decreasing the hepatic
production of VLDL particles and accelerating the
lipolytic processing of VLDL by thermogenic tissues,
thereby lowering atherogenic non-HDL-C in the cir-
culation and reducing its influx into the vessel wall.
Our study complements the previous observations that
rimonabant lowers atherosclerotic plaque development
in ApoE−/− and LDLr−/− mice (15, 16). Since those mice
lack an intact ApoE-LDLr clearance pathway for VLDL
remnants, rimonabant did not reduce plasma choles-
terol in those studies. Rather, the reduction in athero-
sclerosis was explained by enhanced RCT and alowering of inflammation, respectively. This is in sharp
contrast to our study, where we observed a marked
reduction in RCT and a rather increased inflammatory
status, both of which were possibly explained by the
hepatic cholesterol accumulation. More mechanistic
studies are needed to further confirm or refute a role
for RCT and changes in inflammatory status in the
atheroprotective effects of CB1R inverse agonism.
Nevertheless, despite the discrepancies between the
mode of action, our data at least strongly suggest a
role for regulation of VLDL metabolism in the
protecting effects of CB1R antagonism on atheroscle-
rosis development. It is also interesting to note
that a low dose of the cannabinoid derivative delta-
9-tetrahydrocannabinol lowers atherogenesis in
ApoE−/− mice mediated via CB2R signaling on im-
mune cells (41). More research is needed to determine
the relative contribution of CB1R and CB2R signaling
on atherosclerosis development; however, most data
point toward an unfavorable effect of endocannabi-
noid signaling via CB1R.
Rimonabant will most likely not be reintroduced in
the clinic (21). Adverse effects were caused by central
modulation of the CB1R, and therefore, recent efforts
were made to develop a new generation of CB1R an-
tagonists that have limited to no brain penetrance. To
even further improve safety, recent developments
include so-called third-generation peripherally
restricted dual-target CB1R agonists that may also have
increased efficacy for certain metabolic diseases (22).
Furthermore, other strategies to lower endocannabi-
noid tonus include inhibitors of the endocannabinoid
synthesis enzymes (10, 23, 24). Together, these ad-
vancements hold promise for safely and effectively
targeting the endocannabinoid system.
In conclusion, rimonabant decreases atherosclerosis
development in lean hyperlipidemic E3L.CETP mice, as
explained by decreased hepatic VLDL particle pro-
duction and accelerated turnover of VLDL leading to a
reduction in plasma non-HDL-C. Since E3L.CETP mice
are a well-established model for human-like lipoprotein
metabolism and atherosclerosis development, we
anticipate that even in the absence of obesity, CB1R
antagonism may be a promising strategy to combat
CVD, probably through lowering lipids as well as
inflammation. As the clinical development of rimona-
bant was discontinued owing to psychiatric side effects
(21), peripherally restricted CB1R antagonists as well as
inhibitors of the endocannabinoid synthesis enzymes
may provide novel therapeutic handles to inhibit the
endocannabinoid system in humans and may be used as
a safe alternative for rimonabant in the future.
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